Article
PhotoPoint review: Further results found in AMD drug trial Santa Barbara, CA-Miravant Medic
Santa Barbara, CA-Miravant Medical Technologies says 65.6% of patients who were treated three times over 2 years at a lower dose of its PhotoPoint SnET2 photodynamic therapy for wet age-related macular degeneration (AMD) maintained stable vision compared with 39.3% of patients taking placebo.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
